Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Enzyvant
Cary, North Carolina, United Statesenzyvant.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Enzyvant has achieved FDA approval for RETHYMIC®, an allogeneic processed thymus tissue therapy for congenital athymia—a life-threatening pediatric immunodeficiency. The company continues to advance additional candidates targeting rare diseases in immunology and cardiopulmonology. Clinical trials include the evaluation of rodatristat ethyl for pulmonary arterial hypertension with a focus on addressing root causes rather than symptoms. The company merged with Altavant Sciences in December 2022 to expand its rare disease portfolio.
- Therapeutic areas
- Rare DiseasesCardiovascularImmunology
- Modalities
- Tissue-based regenerative therapies (e.g., allogeneic processed thymus tissue)Small molecules (e.g., rodatristat ethyl for pulmonary arterial hypertension)Enzyme replacement therapy (investigational)
- Industry
- Biotech
02
Partnerships
Collaborates with academiaindustry partnersphysician associationsadvocacy groupsgovernment agenciesmanufacturing partnership with parent companies for new facility development
Beyond the preview
Go deeper on Enzyvant.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enzyvant.